403 related articles for article (PubMed ID: 10395322)
1. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy.
Diehl L; den Boer AT; Schoenberger SP; van der Voort EI; Schumacher TN; Melief CJ; Offringa R; Toes RE
Nat Med; 1999 Jul; 5(7):774-9. PubMed ID: 10395322
[TBL] [Abstract][Full Text] [Related]
2. [Immunotherapeutic efficacy of both helper T lymphocytes and cytotoxic T lymphocytes epitopes augmented dendritic cells tumor vaccine on gastric cancer].
Li Q; Zhang Y; Chen XH; Cao WX; Gu QL; Zhu ZG; Liu BY
Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Mar; 9(2):148-51. PubMed ID: 16555158
[TBL] [Abstract][Full Text] [Related]
3. CD40-CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity.
Toes RE; Schoenberger SP; van der Voort EI; Offringa R; Melief CJ
Semin Immunol; 1998 Dec; 10(6):443-8. PubMed ID: 9826577
[TBL] [Abstract][Full Text] [Related]
4. CD40 ligation converts TGF-beta-secreting tolerogenic CD4-8- dendritic cells into IL-12-secreting immunogenic ones.
Zhang X; Kedl RM; Xiang J
Biochem Biophys Res Commun; 2009 Feb; 379(4):954-8. PubMed ID: 19135981
[TBL] [Abstract][Full Text] [Related]
5. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines.
Wan Y; Bramson J; Pilon A; Zhu Q; Gauldie J
Cancer Res; 2000 Jun; 60(12):3247-53. PubMed ID: 10866318
[TBL] [Abstract][Full Text] [Related]
6. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells.
Toes RE; van der Voort EI; Schoenberger SP; Drijfhout JW; van Bloois L; Storm G; Kast WM; Offringa R; Melief CJ
J Immunol; 1998 May; 160(9):4449-56. PubMed ID: 9574550
[TBL] [Abstract][Full Text] [Related]
8. Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses.
Fujiwara H; Yoshioka T; Shima J; Kosugi A; Itoh K; Hamaoka T
J Immunol; 1986 Apr; 136(7):2715-9. PubMed ID: 3005417
[TBL] [Abstract][Full Text] [Related]
9. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
Kikuchi T; Miyazawa N; Moore MA; Crystal RG
Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803
[TBL] [Abstract][Full Text] [Related]
10. Maintenance of memory CTL responses by T helper cells and CD40-CD40 ligand: antibodies provide the key.
Bachmann MF; Hunziker L; Zinkernagel RM; Storni T; Kopf M
Eur J Immunol; 2004 Feb; 34(2):317-26. PubMed ID: 14768036
[TBL] [Abstract][Full Text] [Related]
11. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors.
Toes RE; Blom RJ; Offringa R; Kast WM; Melief CJ
J Immunol; 1996 May; 156(10):3911-8. PubMed ID: 8621930
[TBL] [Abstract][Full Text] [Related]
12. Split peripheral tolerance: CD40 ligation blocks tolerance induction for CD8 T cells but not for CD4 T cells in response to intestinal antigens.
Chung Y; Ko SY; Ko HJ; Kang CY
Eur J Immunol; 2005 May; 35(5):1381-90. PubMed ID: 15827964
[TBL] [Abstract][Full Text] [Related]
13. Cellular interactions in the cytotoxic T lymphocyte response to herpes simplex virus antigens: differential antigen activation requirements for the helper T lymphocyte and cytotoxic T lymphocyte precursors.
Schmid DS; Rouse BT
J Immunol; 1983 Jul; 131(1):479-84. PubMed ID: 6223080
[TBL] [Abstract][Full Text] [Related]
14. A high-affinity T-helper epitope enhances peptide-pulsed dendritic cell-based vaccine.
Li A; Xiong S; Lin Y; Liu R; Chu Y
DNA Cell Biol; 2011 Nov; 30(11):883-92. PubMed ID: 21612399
[TBL] [Abstract][Full Text] [Related]
15. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens.
Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S
Immunol Lett; 2005 Jun; 99(1):85-93. PubMed ID: 15894116
[TBL] [Abstract][Full Text] [Related]
16. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity.
van Mierlo GJ; den Boer AT; Medema JP; van der Voort EI; Fransen MF; Offringa R; Melief CJ; Toes RE
Proc Natl Acad Sci U S A; 2002 Apr; 99(8):5561-6. PubMed ID: 11929985
[TBL] [Abstract][Full Text] [Related]
17. Generation of autoreactive CTL by tumour vaccines containing foreign T helper epitopes.
Steinaa L; Rasmussen PB; Rygaard J; Mouritsen S; Gautam A
Scand J Immunol; 2007 Mar; 65(3):240-8. PubMed ID: 17309778
[TBL] [Abstract][Full Text] [Related]
18. CD4+ T cell responses to CD40-deficient APCs: defects in proliferation and negative selection apply only with B cells as APCs.
Ozaki ME; Coren BA; Huynh TN; Redondo DJ; Kikutani H; Webb SR
J Immunol; 1999 Nov; 163(10):5250-6. PubMed ID: 10553046
[TBL] [Abstract][Full Text] [Related]
19. Donor cell persistence and activation-induced unresponsiveness of peripheral CD8+ T cells.
Ehl S; Barchet W; Oehen S; Aichele P; Hombach J; Hengartner H; Zinkernagel RM
Eur J Immunol; 2000 Mar; 30(3):883-91. PubMed ID: 10741405
[TBL] [Abstract][Full Text] [Related]
20. Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC.
Schoenberger SP; Jonges LE; Mooijaart RJ; Hartgers F; Toes RE; Kast WM; Melief CJ; Offringa R
Cancer Res; 1998 Jul; 58(14):3094-100. PubMed ID: 9679976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]